7. The Role Of Transarterial Chemoembolization In The Treatment Of Hepatocellular Carcinoma In The Stage B Of Bclc
Downloads
Abstract
Hepatocellular carcinoma is the most common primary tumor pathology of the liver (> 85%), an aggressive course with an unfavorable prognosis.
Objective: To analyze the results of transarterial chemoembolization in the intermedi-ate stage of hepatocellular carcinoma.
Materials and methods: The study was conducted on the basis of the JSC “National Scientific Center of Surgery” named after A. N. Syzganov in the period 2013-2018. Statistical calculations were performed using Excel, SPSS Statistics by estimating the survival rate using the Kaplan-Meier method.
Results: The study included 58 patients with HCC in the B stage of BCLC. The average age of the patients was 60.4 years. The follow-up period was 6–64 months. In 42 patients, the test results for viral hepatitis were positive. 58 patients under-went 103 TACE interventions. After chemoembolization, 8 patients subsequently underwent surgery (liver resection). The one-year survival after TACE in the total cohort was 42%, 2-year - 15% and 3-year - 5%, respectively. In patients older than 60 and 70 years, the 3-year and 5-year survival rates were 0%, the one-year survival rate of the subjects studied in the group over 70 years old was 14.3%. The survival rate among patients in stage B on the Chile-Pugh scale was significantly lower to patients in stage A (82% versus 56% for 6 months and 50% versus 31% for the year, respec-tively). Statistically significant differences were found in the group with a substantial increase in AFP (> 1000 IU / ml), the Kaplan-Meier survival curve showed a survival rate of 0% after 18 months since the first TACE. Six months after TACE contrast enhanced CT was performed on 36 patients, of which 15 patients showed positive dynamics, in the form of a reduction in size or transformation of the formation, in 6 patients a negative dynamics in the form of an increase in the size of the formation.
Conclusion: Despite the small number of patients studied, TACE showed good results in the intermediate stage of HCC. Elderly and senile age, a high degree of liver dysfunction, as well as high AFP values are additional factors that dramatically reduce the life expectancy of patients after TACE with HCC in stage B-BCLC.
Keywords
Chemoembolization, Hepatocel-lular carcinoma
References
- Siegel R. et al. Cancer statistics, 2014 // CA. Cancer J. Clin. 2014.Vol. 64, № 1. P. 9–29;
- Ferlay J. et al. Cancer incidence and mortality world-wide: Sources, methods and major patterns in GLO-BOCAN2012 // Int. J. Cancer.
- Bray F. et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008 // Int. J. Cancer.
- Jin-Kyoung Oh, Hai-Rim Shin, Min Kyung Lim et al. Multiplicative synergistic risk of hepatocellular car-cinoma development among hepatitis B and C co-in-fected subjects in HBV endemic area: a community-based cohort study. BMC Cancer 2012; 12:452;
- Aliev, M.A., Sultanaliev, T.A., Seisembaev, M.A et al. The diagnosis and surgical treatment of cavern-ous hemangiomas of the liver. Vestn Khir Im I I Grek 1997; 156(4):12-16;
- Roccarina D, Majumdar A, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with intermediate-stage hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2017, Is-sue
- Farinati f et al. Early and very early hepatocellular car-cinoma: when and how much do staging and choice of treatment really matter? A multi-center study. BMC Cancer 2009; 9: 33
- Arizumi T. et al. Effectiveness of Sorafenib in Pa-tients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepa-tocellular Carcinoma // Liver Cancer TACE Refract. HCC Liver Cancer.
- Llovet J. M., Bruix J. Systematic review of random-ized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. // Hepatology.
- Lencioni R. Management of hepatocellular carci-noma with transarterial chemoembolization in the era of systemic targeted therapy // Crit. Rev. Oncol. Hematol. Elsevier Ireland Ltd,
- Takayasu K. et al. Prospective cohort study of trans-arterial chemoembolization for unresectable hepato-cellular carcinoma in 8510 patients. // Gastroenterol-ogy.
- Burrel M. et al. Survival of patients with hepatocellu-lar carcinoma treated by transarterial chemoemboli-sation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. //J. Hepatol.
- Llovet J. M. et al. Sorafenib in advanced hepatocel-lular carcinoma. // N. Engl. J. Med.
